A Study of Two Iodinated Contrast Agents in Renally Impaired Patients Undergoing Cardiac Angiography

Completed · Phase 4

Conditions studied: CIN

In brief

The main purpose of this study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue or Visipaque in patients with moderate to severe renal insufficiency undergoing cardiac angiography. Serum creatinine will be measured before and up to 48-72 hours after the administration of the contrast agent to evaluate renal function.

Key facts

Study ID

NCT00289029

Run by

Bracco Diagnostics, Inc

People needed

400

Starts

2005-07-01

Expected to finish

2006-06-01

Last updated by the study team

2006-08-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Referred for cardiac angiography; with a documented predose eGFR of greater than or equal to 20 and less than 60 mL/min/1.73m2

You may not qualify if…

• Unstable renal function; concurrent administration of nephrotoxic drugs, undergoing dialysis

Where it is running

• Bracco Diagnostics, Inc — Princeton, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.